Pirtobrutinib: The next generation of BTK inhibitors

The Evolving Role of BTKi's in CLLПодробнее

The Evolving Role of BTKi's in CLL

BTKI inhibitors in the treatment of B-cell lymphoma - Martin Dreyling sessionПодробнее

BTKI inhibitors in the treatment of B-cell lymphoma - Martin Dreyling session

The role of next-generation BTK inhibitors in the treatment of CLLПодробнее

The role of next-generation BTK inhibitors in the treatment of CLL

The benefits of next-generation BTK inhibitors in CLLПодробнее

The benefits of next-generation BTK inhibitors in CLL

BTKI inhibitors in the treatment of B-cell lymphoma - Anthony Mato sessionПодробнее

BTKI inhibitors in the treatment of B-cell lymphoma - Anthony Mato session

Updated results from the BRUIN study: pirtobrutinib in the treatment of MCLПодробнее

Updated results from the BRUIN study: pirtobrutinib in the treatment of MCL

The pharmacokinetics of pirtobrutinibПодробнее

The pharmacokinetics of pirtobrutinib

Next-Generation BTK inhibitors and their role in the CLL treatment landscapeПодробнее

Next-Generation BTK inhibitors and their role in the CLL treatment landscape